» Articles » PMID: 33570624

A Robust Approach for the Generation of Functional Hematopoietic Progenitor Cell Lines to Model Leukemic Transformation

Overview
Journal Blood Adv
Specialty Hematology
Date 2021 Feb 11
PMID 33570624
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Studies of molecular mechanisms of hematopoiesis and leukemogenesis are hampered by the unavailability of progenitor cell lines that accurately mimic the situation in vivo. We now report a robust method to generate and maintain LSK (Lin-, Sca-1+, c-Kit+) cells, which closely resemble MPP1 cells. HPCLSKs reconstitute hematopoiesis in lethally irradiated recipient mice over >8 months. Upon transformation with different oncogenes including BCR/ABL, FLT3-ITD, or MLL-AF9, their leukemic counterparts maintain stem cell properties in vitro and recapitulate leukemia formation in vivo. The method to generate HPCLSKs can be applied to transgenic mice, and we illustrate it for CDK6-deficient animals. Upon BCR/ABLp210 transformation, HPCLSKsCdk6-/- induce disease with a significantly enhanced latency and reduced incidence, showing the importance of CDK6 in leukemia formation. Studies of the CDK6 transcriptome in murine HPCLSK and human BCR/ABL+ cells have verified that certain pathways depend on CDK6 and have uncovered a novel CDK6-dependent signature, suggesting a role for CDK6 in leukemic progenitor cell homing. Loss of CDK6 may thus lead to a defect in homing. The HPCLSK system represents a unique tool for combined in vitro and in vivo studies and enables the production of large quantities of genetically modifiable hematopoietic or leukemic stem/progenitor cells.

Citing Articles

CDK6 kinase inhibition unmasks metabolic dependencies in BCR::ABL1+ leukemia.

Scheiblecker L, Klampfl T, Doma E, Nebenfuehr S, Torres-Quesada O, Strich S Cell Death Dis. 2025; 16(1):107.

PMID: 39966356 PMC: 11836434. DOI: 10.1038/s41419-025-07434-1.


Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells.

Mayer I, Doma E, Klampfl T, Prchal-Murphy M, Kollmann S, Schirripa A Blood. 2024; 144(2):156-170.

PMID: 38684032 PMC: 11302456. DOI: 10.1182/blood.2023021985.


SBNO2 is a critical mediator of STAT3-driven hematological malignancies.

Brandstoetter T, Schmoellerl J, Grausenburger R, Kollmann S, Doma E, Huuhtanen J Blood. 2023; 141(15):1831-1845.

PMID: 36630607 PMC: 10646773. DOI: 10.1182/blood.2022018494.


Isolation, Maintenance and Expansion of Adult Hematopoietic Stem/Progenitor Cells and Leukemic Stem Cells.

Mayer I, Hoelbl-Kovacic A, Sexl V, Doma E Cancers (Basel). 2022; 14(7).

PMID: 35406494 PMC: 8996967. DOI: 10.3390/cancers14071723.


CDK6 Degradation Is Counteracted by p16 and p18 in AML.

Schmalzbauer B, Thondanpallil T, Heller G, Schirripa A, Sperl C, Mayer I Cancers (Basel). 2022; 14(6).

PMID: 35326705 PMC: 8946512. DOI: 10.3390/cancers14061554.


References
1.
Iwasaki H, Akashi K . Myeloid lineage commitment from the hematopoietic stem cell. Immunity. 2007; 26(6):726-40. DOI: 10.1016/j.immuni.2007.06.004. View

2.
Hochhaus A, Spencer A, Goldman J, Melo J . Expression of the LH2 gene in chronic myeloid leukaemia cells. Leukemia. 1996; 10(7):1122-6. View

3.
Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan A, Prchal-Murphy M, Heller G . CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2014; 125(1):90-101. PMC: 4281832. DOI: 10.1182/blood-2014-06-584417. View

4.
Dallas M, Varnum-Finney B, Martin P, Bernstein I . Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1. Blood. 2007; 109(8):3579-87. PMC: 1852253. DOI: 10.1182/blood-2006-08-039842. View

5.
Seita J, Weissman I . Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010; 2(6):640-53. PMC: 2950323. DOI: 10.1002/wsbm.86. View